Clinical Trials · NCT00510224

Sandostatin for Patients With Androgen Independent Prostate Cancer

TerminatedPhase 2Octreotide (Prohibited)
Phase
Phase 2
Recruitment status
Terminated
Sponsor
University of California, San Francisco
Enrollment
13
Start date
Jul 2007
Locations
1 site, United States
Primary endpoint
PSA Response
View Octreotide compound reference